LBPH

Longboard Pharmaceuticals, Inc. (LBPH) | Rumor.io

Longboard Pharmaceuticals

LBPH

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about LBPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Oct 16

Longboard Pharmaceuticals, Inc. ($LBPH) was acquired by H. Lundbeck for $2.6 billion.
$LBPH's acquisition has implications for another company, $DRUG, which has a similar mode of action and was trading at a lower value.
The acquisition of $LBPH has been seen as a catalyst for other undervalued gems, including $XBI, $KLAUS, and potentially others.

Generated by AI

Sentiment

Of the messages about LBPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +14.29
Bearish	—	—	—	0% -14.29

Bullish· Oct 14

Longboard Pharmaceuticals, Inc. (LBPH) was acquired by Lundbeck for $60 per share, resulting in a 47% increase in pre-market stock price.
The acquisition is a significant milestone for LBPH, which has a high potential for success in its Phase 3 trial for Dravet syndrome, with a DEE label and the possibility of better pricing than GW's case.
LBPH's market value is relatively small, making it an attractive target for acquirers, and its story is a good example of the potential for success in the DEE space, which is considered a "gold mine".

Bearish· Jan 4

The company's flagship candidate, bexicaserin, showed only a 50% improvement in a group medicated with the highest dosage allowed, compared to a 20% improvement in a placebo group, and 9 out of 39 patients had to discontinue due to adverse effects.
The stock's price is being artificially inflated by a large public offering, with multiple underwriters, including City, Wedbush, and Cantor, and the company is likely to experience significant dilution.
The stock's price is being manipulated by institutions buying and selling shares to each other, in order to create a false sense of demand and encourage retail investors to buy in.

Generated by AI

Topics

Of the messages about LBPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	17.54%
Announcements	—	—	—	22.81%
Controversies	—	—	—	59.65%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Oct 14

Lundbeck to acquire Longboard Pharmaceuticals (LBPH) for $60/share in cash, valuing the deal at $2.6B.
The acquisition is expected to close in Q4 2024, pending regulatory approvals.
The deal will significantly enhance Lundbeck's neuroscience pipeline, with Longboard Pharmaceuticals adding to its existing portfolio.

Technical Analysis· Jan 2

The price of LBPH has broken through resistance at $18.50 and is now targeting $25.00.
A cup and handle formation has been identified, leading to a price pop.
A potential breakout above $20 is being watched, while a break below $18 could trigger a short.

Generated by AI

Community

Of the messages about LBPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	30.46%
Newcomers	—	—	—	69.54%

Also Discussed

Investors talking about LBPH also mention

#	Name	Attention
1	ROI - RiskOn International, Inc.	——
2	NEXI - NexImmune, Inc.	——
3	AKRO - Akero Therapeutics, Inc.	——
4	Intelligent Living Application Group Inc.ILAG	0%new
5	HeartSciences Inc.HSCS	0%0
6	Compugen LtdCGEN	0%new
7	MURF - Murphy Canyon Acquisition Corp.	——
8	Edgewise Therapeutics Inc.EWTX	0%new
9	Shengfeng Development Ltd.SFWL	0%0
10	C4 Therapeutics IncCCCC	0%new